Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032385 | 0.81 | MAPT (0.40) | GSK3BKDM4EALDH1A1GAAMAPT | |
| SCHEMBL8807640 | 0.81 | HSD17B10 (0.52) | KDM4EHSD17B10ALDH1A1CYP1A2GAA | |
| SCHEMBL5794646 | 0.78 | PGR (0.43) | KDM4EHSD17B10ALDH1A1CYP1A2GAA | |
| SCHEMBL22393852 | 0.78 | PGR (0.37) | GSK3BKDM4EALDH1A1MAPTPARP1 | |
| SCHEMBL7026627 | 0.78 | IDH1 (0.35) | GSK3BKDM4EHSD17B10ALDH1A1CYP1A2 | |
| SCHEMBL30504352 | 0.78 | PGR (0.37) | GSK3BKDM4EALDH1A1MAPTPARP1 | |
| SCHEMBL17883917 | 0.78 | KDM4E (0.36) | GSK3BKDM4EALDH1A1PARP1HPGD | |
| SCHEMBL27101008 | 0.78 | TYMP (0.42) | KDM4EHSD17B10ALDH1A1CYP1A2GAA | |
| SCHEMBL16166967 | 0.77 | KDM4E (0.51) | KDM4EALDH1A1PARP2GRIN2DGRIN3B | |
| SCHEMBL24665377 | 0.77 | GSK3B (0.46) | GSK3BKDM4EHSD17B10PARP4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3960735-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20210113578-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC | 2021-04-22 | — | — | US | disclosed |
| US-20210113578-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC | 2021-04-22 | — | — | US | disclosed |
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2021-03-25 | — | — | US | disclosed |
| US-10912779-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2021-02-09 | — | — | US | disclosed |
| US-10912779-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2021-02-09 | — | — | US | disclosed |
| US-10869872-B2 | — | — | 2020-12-22 | — | — | US | disclosed |
| US-10869872-B2 | — | — | 2020-12-22 | — | — | US | disclosed |
| EP-3658586-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | ENCEFA (FR) | 2020-06-03 | — | — | EP | disclosed |
| CN-111108127-A | Compounds that specifically bind CD38 for use in the treatment of neurodegenerative and inflammatory diseases | ENCEFA公司 | 2020-05-05 | — | — | CN | disclosed |
| US-20170027953-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9499495-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499495-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499495-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | ASANA BIOSCIENCES, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160068496-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068496-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068496-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-03-10 | — | — | US | disclosed |
| EP-2984088-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | Asana BioSciences, LLC (US) | 2016-02-17 | — | — | EP | disclosed |
| WO-2014169167-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2014-10-16 | — | — | WO | disclosed |
| WO-2014169167-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068496-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | GSK3B 1091/4885KDM4E 376/4885HSD17B10 4635/4885 |
| US-20210087290-A1 | COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES | CD38, TRPC1, TRPC4 | GSK3B 4243/4885KDM4E 3720/4885HSD17B10 3083/4885 |
| US-10869872-B2 | — | NRAS, KRAS, BRAF | GSK3B 1152/4885KDM4E 293/4885HSD17B10 4756/4885 |
| US-20170027953-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | GSK3B 1084/4885KDM4E 386/4885HSD17B10 4634/4885 |
| US-20210113578-A1 | QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS | NRAS, KRAS, BRAF | GSK3B 1084/4885KDM4E 386/4885HSD17B10 4634/4885 |
| US-10912779-B2 | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways | NRAS, KRAS, BRAF | GSK3B 1084/4885KDM4E 386/4885HSD17B10 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.